ME Therapeutics Holdings Inc.
METXF
$2.95
$0.000.00%
OTC PK
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -29.26% | -14.95% | -17.22% | 10.22% | 90.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.95% | -4.78% | -0.35% | 38.83% | 113.97% |
| Operating Income | 18.95% | 4.78% | 0.35% | -38.83% | -113.97% |
| Income Before Tax | 17.06% | 81.40% | 81.76% | 80.25% | 77.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.06% | 81.40% | 81.76% | 80.25% | 77.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.06% | 81.40% | 81.76% | 80.25% | 77.92% |
| EBIT | 18.95% | 4.78% | 0.35% | -38.83% | -113.97% |
| EBITDA | 20.22% | 5.28% | 0.44% | -38.81% | -113.97% |
| EPS Basic | 34.85% | 88.29% | 88.51% | 87.61% | 83.78% |
| Normalized Basic EPS | -114.45% | 29.22% | 30.93% | 15.63% | 173.36% |
| EPS Diluted | 39.96% | 87.99% | 87.87% | 86.97% | 81.79% |
| Normalized Diluted EPS | -114.45% | 29.22% | 30.93% | 15.63% | 173.36% |
| Average Basic Shares Outstanding | 21.56% | 30.49% | 62.67% | 112.63% | 91.42% |
| Average Diluted Shares Outstanding | 21.56% | 30.49% | 62.67% | 112.63% | 91.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |